Overcoming primary and acquired resistance to anti-PD-L1 ... - Nature
Oct 27, 2020 · Evidence indicates crucial roles of Batf3-dependent conventional type-1 dendritic cells (cDC1s) for inducing antitumor T-cell immunity; however, strategies to maximize cDC1 engagement remain...
Tumor-repopulating cell-derived microparticles elicit cascade ...
Oct 25, 2023 · Here, we developed tumor-repopulating cell (TRC)-derived microparticles with exceptional tumor targeting to deliver doxorubicin (DOX@3D-MPs) for improve anti-PD-1 therapy. DOX@3D-MPs...
Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor …
Jun 1, 2022 · In this study, we demonstrated that CT-26 colon cancer and 4T1 triple negative breast cancer have different sensitivity to anti-PD-1 and anti-CTLA-4 therapy. CT-26 tumor highly responds to anti-CTLA-4 therapy whereas it is less sensitive to anti-PD-1.
Overcoming resistance to checkpoint blockade therapy by
Nov 9, 2016 · We show that mice bearing 4T1 breast carcinoma are resistant to anti-PD-1 (programmed cell death protein 1) or anti-CTLA4 (cytotoxic-T-lymphocyte-associated protein 4) therapy (Fig. 1a and...
Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 …
In the current study, we show that repeated dosing with xenogeneic PD-1 mAbs induces rapid fatal hypersensitivity in 4T1 tumor-bearing mice but that this does not occur in a less inflammatory tumor models or with xenogeneic isotype controls.
TTK inhibition activates STING signal and promotes anti-PD1 ...
Jan 29, 2024 · TTK inhibitor suppresses 4T1 tumor growth dependent on CD8 + T cells and modulates tumor immune microenvironment. Inhibition of TTK synergistically enhances the effectiveness of anti-PD1 therapy in subcutaneous 4T1 tumor model.
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
The addition of the anti-PD-L1 drug atezolizumab to NAB-paclitaxel chemotherapy has been shown to significantly improve PD-L1-positive (PD-L1+) metastases and improve overall survival (OS) in patients with advanced TNBC (Schmid et al., 2018).
Repeated PD-1/PD-L1 monoclonal antibody administration …
Aug 12, 2015 · This study highlights a previously uncharacterized fatal hypersensitivity exacerbated by the PD-1/PD-L1 axis in the broadly used 4T1 tumor model as well as an interesting relationship between this particular class of checkpoint blockade and tumor-dependent immunomodulation.
Pingyangmycin enhances the antitumor efficacy of anti-PD-1 …
PYM markedly enhanced the therapeutic efficacy of anti-PD-1 antibody against 4T1 breast cancer. The calculated CDI (coefficient of drug interaction) indicated synergistic effect.
Therapy With Carboplatin and Anti-PD-1 Antibodies Before …
We demonstrated that treatment with CBDCA and anti-PD-1 before surgery increased the ratio of CD103 + DC in total DC in the secondary 4T1 breast tumors by ~1.5-folds (Figures 7B,C, p < 0.01) at Day 35 after the primary tumor implantation.